Skip to main content
Figure 1 | Vascular Cell

Figure 1

From: Vaccines targeting the neovasculature of tumors

Figure 1

Major mechanistic immune pathways of anti-angiogenic vaccines and their targets. Vaccine antigens are processed by antigen processing cells such as dendritic cells and presented to T cells. Depending on the antigen, the route of administration, and the vector, peptide presentation to either major histocompatibility complex (MHC) class I or II occurs, with subsequent interaction with T-cell receptors on CD4+ or CD8+ cells. Cytotoxic CD8+ T cells recognize and lyse tumor endothelial cells directly by perforin-mediated and Fas-mediated cytotoxic mechanisms. CD4+ T-helper cells, through release of different cytokines, can induce Th1 or Th2 responses that stimulate B-cells to produce antibodies and/or activate NK cells and macrophages to inhibit tumor endothelium. Representative targets related to endothelial and cancer cells and their environment for anti-angiogenic vaccines are depicted. Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 2010. All Rights Reserved.

Back to article page